Paysign, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PAYS research report →
Range $15 – $15
Price Chart
About the company
Paysign, Inc. provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. The company offers solutions for corporate rewards, prepaid gift cards, general-purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card and software solutions.
- CEO
- Mark Newcomer
- IPO
- 2007
- Employees
- 226
- HQ
- Henderson, NV, US
Get TickerSpark's AI analysis on PAYS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $556.60M
- P/E
- 27.58
- Fwd P/E
- 26.64
- PEG
- 0.18
- P/S
- 5.21
- P/B
- 8.60
- EV/EBITDA
- 15.18
- Div Yield
- 0.00%
- Gross Margin
- 58.55%
- Op Margin
- 20.80%
- Net Margin
- 18.47%
- ROE
- 35.29%
- ROIC
- 23.60%
Latest fiscal year · YoY change
- Revenue
- $82.03M+40.5%
- Gross Profit
- $40.40M+25.5%
- Op Income
- $7.24M
- Net Income
- $7.55M+97.9%
- EPS
- $0.14+95.3%
- OCF Growth
- +128.6%
- FCF Growth
- +280.7%
- 52W High
- $16.15
- 52W Low
- $3.08
- 50D MA
- $13.37
- 200D MA
- $8.85
- Beta
- 0.87
- RSI (14)
- 31
- Avg Volume
- 1.02M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Paysign posted record third-quarter revenue and profitability as patient affordability more than doubled, outweighing a planned fourth-quarter loss of plasma centers.· November 9, 2026
- Revenue rose 42.6% year over year to $30.8 million, with net income up to $6.7 million and EPS of $0.11.
- Gross margin expanded to 64.7% from 56.3%, and operating margin jumped to 23.8% from 7.3%.
- Patient affordability was the main growth engine: revenue increased 109.8% to $16.6 million and active programs reached 167.
- Plasma revenue also grew 7.5% to $13.8 million, but one customer will move 113 centers to another provider in Q4.
- Management kept full-year revenue guidance at $114 million to $117 million while raising confidence in margins and profitability despite the plasma transition.
Third-quarter revenue increased 42.6% year over year to $30.8 million. Gross margin expanded to 64.7% from 56.3%, operating margin rose to 23.8% from 7.3%, and adjusted EBITDA increased 118% to $11 million from $5 million. GAAP net income was $6.7 million, or $0.11 per diluted share, versus $2.2 million, or $0.04 per diluted share, a year ago. Patient affordability revenue climbed 109.8% to $16.6 million, while plasma revenue rose 7.5% to $13.8 million. For the fourth quarter, management expects the 113-center transition to reduce revenue by $1.5 million and gross profit by $700,000. Full-year 2026 guidance is revenue of $114 million to $117 million, gross profit margin of 63.5% to 64.5%, GAAP net income of $23 million to $24 million, or $0.37 to $0.38 per diluted share, and adjusted EBITDA of $38.5 million to $40 million. Year-end operating expectations are 190 to 195 active patient affordability programs and 445 to 450 plasma centers.
Mark Newcomer framed the quarter as validation of Paysign’s strategy to pair its mature plasma business with a faster-growing, higher-margin patient affordability platform. He emphasized that patient affordability is driving growth, margin expansion, and operating leverage, while plasma remains a cash-generative base. He also said the company is building Apherion for future growth and that interest in the product is strong in both the U.S. and the EU, with a quicker-than-expected ramp possible once approved.
Jeffery Baker said the quarter came in above the high end of guidance across revenue, operating margin, and net income, and highlighted that operating margin more than tripled to 23.8%. He pointed to the mix shift toward pharma revenue, which carries higher gross margins, and slower growth in costs as key drivers of the 64.7% gross margin. He also noted a clean balance sheet with $34.5 million in unrestricted cash and no bank debt, while restricted cash was $201.8 million. For the fourth quarter, he quantified the plasma transition impact at $1.5 million of revenue and $700,000 of gross profit, then reiterated full-year targets for revenue, margin, net income, adjusted EBITDA, and a tax rate of about 21.3%.
Analysts focused on whether the lost plasma centers could be replaced, the timing of patient affordability growth into 2027, and the status of Apherion’s regulatory review. Management said there is “absolutely” enough plasma business out there to replace the lost centers over time, but timing will depend on transitions and customer discussions. On patient affordability, management said program wins are typically back-end loaded in the year and that utilization of the platform is improving as more programs are added. On Apherion, they said there is no timeline from regulators yet, but client interest remains high and they expect a quicker ramp once approval comes through.
The core bullish point is that patient affordability is scaling quickly, with revenue more than doubling, claims up about 55%, and program count expected to reach 190 to 195 by year-end. Management also said the business is producing meaningful leverage, with expanding gross and operating margins and strong adjusted EBITDA growth. They view plasma as a stable cash source and believe Apherion could become another higher-margin growth vector once regulatory review is complete.
The main risk is the planned loss of 113 plasma centers in the fourth quarter, which management says will reduce revenue and gross profit next quarter. Apherion remains under regulatory review with no timeline, so that potential growth driver is still uncertain. Management also acknowledged that replacing lost plasma centers will take time and depends on customer transitions rather than immediate conversions.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 60.3%
- Shares Outstanding
- 56.85M
- Float Shares
- 34.26M
of shares held by institutions
140 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Topline Capital Management, LLC | 4.25M | ▼ 392.06K |
| Blackrock, Inc. | 3.16M | ▲ 77.71K |
| Punch & Associates Investment Management, Inc. | 2.06M | ▼ 12.47K |
| Vanguard Capital Management LLC | 1.93M | ▲ 328.56K |
| Vanguard Group Inc | 1.87M | ▲ 45.95K |
| Geode Capital Management, LLC | 1.19M | ▲ 147.30K |
| Palisades Investment Partners, LLC | 1.13M | ▲ 129.44K |
| Thompson Siegel & Walmsley LLC | 1.10M | ▼ 314.38K |
| Renaissance Technologies LLC | 1.04M | ▼ 30.09K |
| State Street Corp | 861.28K | ▲ 17.62K |
| Dimensional Fund Advisors LP | 835.87K | ▲ 110.42K |
| Arrowstreet Capital, Limited Partnership | 834.79K | ▼ 69.71K |
Held by 143 ETFs
Biggest fund positions in PAYS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 16, 26 | Herman Joan M | sell | 30,000 |
| Oct 9, 26 | Newcomer Mark | sell | 50,000 |
| Sep 15, 26 | Herman Joan M | sell | 21,004 |
| Sep 16, 26 | Herman Joan M | sell | 38,900 |
| Sep 8, 26 | Ngo Michael C | sell | 70,075 |
| Sep 9, 26 | Ngo Michael C | sell | 79,925 |
| Mar 19, 25 | Ngo Michael C | other | 2,500,000 |
| Mar 19, 25 | Ngo Michael C | other | 500,000 |
| Mar 31, 26 | Ngo Michael C | other | 38,664 |
| Mar 19, 25 | Ngo Michael C | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PAYS coverage
Recent articles, reports, and earnings notes.
No research on PAYS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PAYS report →Paysign: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 14
Is Paysign (PAYS) a Solid Growth Stock? 3 Reasons to Think "Yes"
zacks.com · Nov 13
All You Need to Know About Paysign (PAYS) Rating Upgrade to Buy
zacks.com · Nov 13
Down 39.2% in 4 Weeks, Here's Why Paysign (PAYS) Looks Ripe for a Turnaround
zacks.com · Nov 13
Paysign's Post-Q3 Selloff Opens An Opportunity
seekingalpha.com · Nov 11
Paysign, Inc. (PAYS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
Paysign Q3 Earnings Call Highlights
marketbeat.com · Nov 9
Paysign Reports Record Third Quarter 2026 Revenue of $30.8 Million, Up 43%; Operating Margin More Than Triples to 23.8%
businesswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.